|1.69|| 0.00 / 0.00%|
Miscellaneous Commercial Services
PharmAthene, Inc. operates as a biodefense company, which is engaged in the development and commercialization of medical countermeasures against biological and chemical threats. Its biodefense candidates include Anthrax vaccines including SparVax, a second generation liquid recombinant protective antigen, anthrax vaccine and a next generation lyophilized anthrax vaccine containing rPA; recombinant butyrylcholinesteras bioscavenger, a medical counter measure for nerve agent poisoning by organ phosphorous compounds, including nerve gases and pesticides; and valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection. The company was founded in March 2001 and is headquartered in Annapolis, MD.
|John M. Gill||President, Chief Executive Officer & Director|
|Jeffrey Michael Jones||Chief Operating Officer & Vice President|
|Philip MacNeill||CFO, Secretary, Treasurer & Vice President|